Introducing Idrasil™

The first prescription only medical cannabis.


Founded in
2010
Private
Ownership
Manufacturers
of Idrasil™

About us

C3® International, Inc. was formed to leverage first mover advantage and play a leadership role in the emergent cannabinoid therapeutics health sector. C3® is the manufacturer of Idrasil™ the first standardized form of medical cannabis.
Learn more at Idrasil.com

Research

Clinical EndoCannabinoid Deficiency (CECD)

Subsequent research has confirmed that underlying endocannabinoid deficiencies indeed play a role in migraine, fibromyalgia, irritable bowel syndrome and a growing list of other medical conditions.
READ MORE


Executive Staff

C3® International, Inc. is the leader in the emerging cannabinoid sector holding intellectual property on it's flag ship product Idrasil™.